AVXL Anavex Life Sciences Corp

$AVXL I still expect my AVXL investment to pay off. Strange as it seams, I can’t think of a stock with better price appreciation potential than AVXL. With AVXL’s legacy staff now out of the picture, and all intellectual property still fully under the company’s control, and no competitors with a proven technological advantage, I think success is possible. Let’s get some well regarded hedge funds to invest in Anavex, and then move ahead under their watchful eyes.

$AVXL We've gone from a CEO that in all earnestness could not even "Talk the Talk" to one who is mastering the "Walk the Walk." One can't emphasize enough the importance of demonstrating one's beliefs and promises through actions not words. Well done TK!

$AVXL I did a deep dive into Anavex’s steep price decline, this is what I found. This sudden drop is tied to official events, most notably: 1.) The recent Wave of Class Action Lawsuits: On 9/30 and 10/1, multiple prominent law firms filed class action lawsuits against Anavex. 2.) These lawsuits are based on the company's own prior SEC filings. They point directly to Anavex’s admission of "material weaknesses in internal control over financial reporting” and the fallout surrounding the termination of Missling for cause earlier this year. 3.) The termination of C.M. on April 30th was for conduct "inconsistent with Company Policy," a development the lawsuits claim was hidden until subsequent delayed regulatory filings forced the disclosure, harming shareholders. 4.) Seizing on these lawsuits, off-exchange short selling for Anavex has turned highly aggressive — all thanks to the misdeeds of Christoper Missling. I believe in the science, I am long Anavex, and I ain’t selling one share!

$AVXL For those concerned that the new board is "refusing to communicate," understanding Delaware corporate law and SEC filing mechanics explains why no public statement has been made yet. Post-proxy boards follow a standard 2-meeting playbook (Harvard Law School Forum on Corp. Governance and NACD guidelines): Meeting 1 (Days 0-2): Procedural. Certified election count & signing continuity (8-K Sept 28). 10-Day Gate: Clear diligence & get CIK codes to file Form 3 by statutory deadline. Senderowicz & Patel filed Oct 5 on schedule. Meeting 2 (Days 5-10): Substantive session to: • Reconstitute Audit/Comp committees (Nasdaq 5605). • Resolve CEO mandate (DGCL § 142): decide interim elevation vs. external search. • Align on 10-K audit for FY ended Sept 30. Management cannot front-run a new board before this wraps. SEC rules require Form 8-K within 4 business days of board action. The stock price reflects a temporary transition window, but governance moves on statutory calendars, not sentiment.

$AVXL FYI, all Alz stocks have taken A beating over the past month notably avxl, axsm and anvs. Nothing has changed w the science or trial data or the plan moving forward. In fact the next 3 months have multiple catalysts inc potentially an adaptive, accelerated approval trial design for Alz. That trial (which would include AbClear3 for accelerated) at this stage, added 15-20b to each of the MAB companies. It’s a game changer if awarded. Be certain, that’s the data driven direction Anavex will be pursuing. We will know soon enough. Team is collaborating w regulators to deliver on 3 new trials. Amazing what can be accomplished and time saved over the lifecycle when you engage upfront with those who approve. Ask for forgiveness later doesn’t work in this space. GLTA

$AVXL I keep thinking about Terrie's comment on the call where they actually talked and how she said she is even more impressed with the drug with the work she has done after becoming president.

$AVXL This Is The Way. While I realize this great press release isn't enough to wipe away the previous negative sentiment the market has for AVXL, it is the right direction. A few more positive steps like this, all the missteps will be forgotten, eventually.

$AVXL When this goes negative, I am going to own the whole company. It will be like oil futures that one day. ;) I know this company is a shit show but this drug is amazing. Hopefully we get news on the trials soon.

$AVXL I bought 4K more shares at $2.25, a little early admittedly, but riding this out. I remember buying around 8k shares around the same price way back when and it was the Best Buy ever, although I didn’t ever sell and capitalize on them. This will turn around, just not fast. Hope the longs here are all doing well!

$AVXL Once Blarcamesine sees the light of day, the approvals will fall via off label authorizations. With little to no down side to taking this medication, companionate use and right to try will certainly be popular options for the sick. Dosage will be the only challenge. Good luck fell “bag holders” Possibly.. soon to be money bag holders. I’m about to double down… again. Fair skies coming into Barcelona!

$AVXL Top line results of the Blarcamesine Phase 2b/3 Alzheimers trial were first presented on December 1, 2022 at CTAD. Dr. Stepen MacFarlane was the presenter. On December 5, 2022 Anavex hosted a conference call between CEO Christopher Missling, Dr. Timo Grimmer, Dr. George Perry, and investors. Doctors Grimmer and Perry didn't think Blarcamesine could be approved based on the trial's results. However, Dr. Grimmer did mention that he thought a pathway for conditional approval was possible, w/the requirement that Anavex initiate a confirmatory trial. Both doctors said that Blarcamesine would eventually be approved for the treatment of Alzheimers Disease. Their confidence in the drug should give investors confidence.

$AVXL The rational ones all left a long time ago and as I am doing only check in from time to time to see if there is still a pulse here. Barely. Anavex will be fine, folks. Maybe not in the timeline some hoped for but the drug most likely will work in the next trial, the issue wasn't data fabrication but rather too small of a trial because our CEO was hoping the EMA or FDA would buy into "precision medicine" allowing him to save time and money with a back-door path to approval. Our new team is doing it the traditional way which takes time and money. Fortunately we have money so dilution won't be too extreme. We also have a drug compound that I believe for a P2 is still very desirable so I'd expect a bidding war for a partnership. For the price to be trading .25 above cash is interesting. Either the data is completely made-up or there is an arbitrage opportunity about to take place with the options market.

$AVXL It’s been a very busy time. I guess I’m lucky to have a medical problem that was corrected by heart catheter. AD? They all chase. But we have Blarcamesine. All around us, fuckery. But we still have it. I still have a significant stake in this company. I’m about to get a very nice bonus… which will go to more shares. My average should be around $2.50 I also think that Blarcamesine has other benefits not yet discovered. Just like GLP1 drugs. I’m very optimistic.

$AVXL If we have 20 more 16% days in a row, the share price will be back at $28. After that we can go back to the normal appreciation .

$AVXL These studies were two things Chris should have done as a matter of simple professional and pharmaceutical competence. Analysis isn't even complete in a way we could know all is well, but if she wants to mention every small update as it happens, I'm definitely not mad about it.

$AVXL We can assume from consistent sharing that TK will immediately announce pediatric addition to Rett as soon as she knows in November. I feel as though this may be a small catalyst, as it/she may signal something broader about the FDAs evaluation of the previous Rett data and what it probably suggests is true about 2-73.

$AVXL I own a ton of this stock, but with the PR yesterday and this artificial pullback it's very tempting to pull out the checkbook and add some more.

$AVXL I bought another 10k shares, up to 150k now. Be greedy when everyone is fearful. Only has to get to $2.60 to double your money. 😎

$AVXL Best PR/good news we have had in a long time. Finally heading in the right direction 👆🥂 Still a long road ahead.

$AVXL One task cleared. Seems like she's on task and kicking ass so far. These no-nonsense bits will keep coming, short and sweet. FDA suits probably glad it's not Chris. 🤷🏻‍♂️